Home
About Us
In this Issue
Previous Issue
Editorial Board
How to Contribute
Advertise with Us
Editorial Calendar
Subcribe Now
Global Healthcare Releases provided by Business Wire

 The Publication & Databases on Biotechnology in the Asia Pacific
 
 More free   feature articles 
  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

EYE on CHINA
Daiichi Sankyo launches Silodosin for the treatment of Dysuria in China
Daiichi Sankyo Company Limited announced that its subsidiary, Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd., has begun marketing silodosin (Chinese product name: 优利福®), which was developed for treatment of dysuria associated with benign prostatic hyperplasia.

Silodosin is a selective alpha 1A-adrenoceptor antagonist existing mainly in the prostate which was originally discovered by Kissei Pharmaceutical Co., Ltd. By inhibiting the alpha 1A-adrenergic receptor, silodosin relieves tension in the prostate, lessens pressure and reduces urethral resistance to treat dysuria associated with benign prostatic hyperplasia. Silodosin has been jointly marketed in Japan since May 2006 by Daiichi Sankyo and Kissei Pharmaceutical under the brand name, Urief®.

Through the launch of silodosin and other innovative pharmaceuticals, Daiichi Sankyo is committed to increasing its presence in the fast-growing Chinese pharmaceutical market.

Click here for the complete issue.


About Us | How to Contribute | How to Advertise With Us | Contact Us |

"The views expressed here does not necessarily reflect the views of Asia Pacific Biotech News or its staff."
Copyright © 2014 World Scientific Publishing Co. All rights reserved.